BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1538438)

  • 1. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.
    Splinter TA; Scher HI; Denis L; Bukowski R; Simon S; Klimberg I; Soloway M; Vogelzang NJ; van Tinteren H; Herr H
    J Urol; 1992 Mar; 147(3):606-8. PubMed ID: 1538438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
    Soloway MS; Lopez AE; Patel J; Lu Y
    Cancer; 1994 Apr; 73(7):1926-31. PubMed ID: 8137219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
    Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
    Hatcher PA; Hahn RG; Richardson RL; Zincke H
    Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer.
    Herr HW; Scher HI
    J Clin Oncol; 1994 May; 12(5):975-80. PubMed ID: 8164050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic chemotherapy for muscle invasive bladder cancer.
    Ondrus D; Hornák M; Bárdos A; Ondrus B
    Neoplasma; 1994; 41(5):263-8. PubMed ID: 7854496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.
    Connor JP; Olsson CA; Benson MC; Rapoport F; Sawczuk IS
    Urology; 1989 Dec; 34(6):353-6. PubMed ID: 2595880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results.
    Vikram B; Malamud S; Silverman P; Hecht H; Grabstald H
    J Urol; 1994 Mar; 151(3):602-4. PubMed ID: 8308967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
    Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
    J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
    Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
    J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study.
    Dreicer R; Messing EM; Loehrer PJ; Trump DL
    J Urol; 1990 Nov; 144(5):1123-6; discussion 1126-7. PubMed ID: 2231884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
    Higano CS; Tangen CM; Sakr WA; Faulkner J; Rivkin SE; Meyers FJ; Hussain M; Baker LH; Russell KJ; Crawford ED;
    Cancer; 2008 May; 112(10):2181-7. PubMed ID: 18404692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of methotrexate, vinblastine, adriamycin, and cisplatin in combination with radiation and hyperthermia as neo-adjuvant therapy for bladder cancer.
    Noguchi S; Kubota Y; Miura T; Shuin T; Hosaka M
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S63-5. PubMed ID: 1394821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup.
    Dreicer R; Kollmorgen TA; Smith RF; Williams RD
    J Urol; 1993 Sep; 150(3):849-52. PubMed ID: 8345598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.